China is the country with the highest number of diabetics worldwide, with around *** million people suffering from the disease. By the year 2050, it is predicted that China will have around *** million people with diabetes. Death from diabetes Diabetes is one of the leading causes of death worldwide, accounting for **** million deaths in 2021. Diabetes at least doubles one’s chance of dying prematurely, and many places in the world lack appropriate treatment options. The highest number of deaths from diabetes comes from the Western Pacific, where around *** million people died from the disease in 2024. Obesity One of the biggest risk factors for developing diabetes is being overweight or obese. Rates of obesity have increased in recent years in many countries around the world. In the United States, for example, it is estimated that around ** percent of the adult population was obese in 2023, compared to ** percent of the population in 2011.

In 2024, Pakistan had the highest prevalence of diabetes worldwide, with around ** percent of the population suffering from the disease. Diabetes mellitus, or simply, diabetes, refers to a group of metabolic disorders that cause high blood sugar levels. Diabetes can be prevented and treated though exercise, maintaining normal body weight, and healthy eating, but is usually managed with insulin injections. Costs As of 2024, there were almost *** million people worldwide who had diabetes. With such a huge number of people suffering from this disease, it is no surprise that spending on diabetes can be very high. It is estimated that the United States alone spent around ***** billion U.S. dollars on diabetes health expenditure in 2024. The countries with the highest spending per patient with diabetes include Switzerland, the United States, and Norway. Death Diabetes is among the leading ten causes of death worldwide, accounting for around **** million deaths in 2021. Complications resulting from diabetes include chronic kidney disease, stroke, and cardiovascular disease. The risk of early death is at least doubled among those with diabetes. The Western Pacific reports the highest number of deaths from diabetes, followed by North America and the Caribbean.

By 2050, the Western Pacific region is forecast to have the highest number of diabetic people worldwide, with some 254 million people aged between 20 and 79 years. Diabetes in the future Between 2024 and 2050, the number of diabetics is set to increase in all regions worldwide. Diabetes rates are expected to increase the most in Africa, by roughly 142 percent. Throughout this period, Europe is projected to show the smallest increase, with about 10 percent. In 2050, the countries with the highest number of diabetics are expected to be China with some 168 million and India with about 157 million. At that time, about 43 million people are projected to have diabetes in the United States. Children with type 1 diabetes In 2024, the country with the highest estimated number of children and adolescents (between the ages of 0 and 19) with type 1 diabetes was India, which had some 301 thousand diabetic children and adolescents. The United States came second with around 197 thousand. Considering the U.S. population is significantly smaller than that of India, there is a higher percentage of children with type 1 diabetes in the United States.

The average for 2021 based on 11 countries was 9.58 percent. The highest value was in Malaysia: 19 percent and the lowest value was in Vietnam: 6.1 percent. The indicator is available from 2000 to 2021. Below is a chart for all countries where data are available.

Diabetes prevalence is projected to increase across all world regions by 2050, with the Middle East and North Africa expected to face the highest rates at 21 percent. This alarming trend highlights the growing global health challenge posed by diabetes, which already affects hundreds of millions of people worldwide and strains healthcare systems. Global impact and economic burden The number of diabetics globally is set to rise from nearly 589 million in 2024 to around 853 million by 2050. This surge in cases is accompanied by a significant economic burden, with global expenditures for diabetes treatment expected to grow from about 1.02 trillion U.S. dollars in 2024 to approximately 1.04 trillion U.S. dollars by 2050. The United States alone is projected to spend around 404.5 billion U.S. dollars on diabetes-related healthcare in 2024, underscoring the massive financial implications of this chronic condition. Regional disparities and future outlook While the Middle East and North Africa region is projected to have the highest diabetes prevalence by 2050, other regions will also see substantial increases. Africa is expected to experience a 142 percent rise in diabetic cases from 2024 to 2050, despite having the lowest prevalence among world regions. China is anticipated to remain the country with the highest number of diabetics, reaching approximately 168 million cases by 2050. Notably, Pakistan is forecast to surpass the United States in terms of diabetic population by mid-century, reflecting shifting global health dynamics and the need for targeted interventions in developing nations.

Portugal had the highest prevalence of diabetes in Europe among their adult population with **** percent living with diabetes, as of 2024, Croatia followed with the second-highest share at **** percent. Conversely, Ireland was the country with the lowest prevalence of diabetes in Europe at *** percent. Diabetes-related deaths The highest number of diabetes-related deaths in Europe, at almost ******, was recorded in Germany in 2024. Italy and France followed, with roughly *******and ****** deaths, respectively. Diabetes risk factors in Europe One of the major contributing factors to type 2 diabetes is being overweight or obese. As of 2022, Greece had the highest share of overweight population across Europe, with *****percent. The lack of sports and exercise is also another risk factor. As of 2022, Portugal was the European country with the highest share of people never exercising or engaging in sports, with ** percent.

The average for 2021 based on 27 countries was 6.24 percent. The highest value was in Spain: 10.3 percent and the lowest value was in Ireland: 3 percent. The indicator is available from 2000 to 2021. Below is a chart for all countries where data are available.

The average for 2021 based on 20 countries was 8.73 percent. The highest value was in Mexico: 16.9 percent and the lowest value was in Ecuador: 4.4 percent. The indicator is available from 2000 to 2021. Below is a chart for all countries where data are available.

In 2021, close to ** percent of the population in Pakistan had diabetes. In comparison, Vietnam had the lowest prevalence of diabetic people across the Asia-Pacific region that year, approximately *** percent.

In 2024, India had the highest number of children and adolescents aged under 20 who were living with type 1 diabetes, with around 301,000 cases. At that time, an estimated 197,000 children and adolescents in the United States had type 1 diabetes. This statistic shows the countries with the highest number of children and adolescents aged 0 to 19 years with type 1 diabetes in 2024.

This statistic shows the top 10 countries based on number of new cases of type 1 diabetes per 100,000 children aged 0 to 14 years, in 2021. Finland had the highest rate with 52.2 new cases per 100,000 children per year.

*(Age-standardised incidence rates per 100,000 individuals per year with 95% confidence intervals. † For cells labeled as NA, 95% CIs could not be estimated as there was only 1 data point).

*(Age-standardised incidence rates per 100,000 individuals per year with 95% confidence intervals. † For cells labeled as NA, 95% CIs could not be estimated as there was only 1 datapoint).

The objective of this study was to compare the effect of diabetes and pathologies potentially related to diabetes on the risk of infection and death from COVID-19 among people from Highly-Developed-Country (HDC), including Italians, and immigrants from the High-Migratory-Pressure-Countries (HMPC). Among the population with diabetes, whose prevalence is known to be higher among immigrants, we compared the effect of body mass index among HDC and HMPC populations. A population-based cohort study was conducted, using population registries and routinely collected surveillance data. The population was stratified into HDC and HMPC, according to the place of birth; moreover, a focus was set on the South Asiatic population. Analyses restricted to the population with type-2 diabetes were performed. We reported incidence (IRR) and mortality rate ratios (MRR) and hazard ratios (HR) with 95% confidence interval (CI) to estimate the effect of diabetes on SARS-CoV-2 infection and COVID-19 mortality. Overall, IRR of infection and MRR from COVID-19 comparing HMPC with HDC group were 0.84 (95% CI 0.82–0.87) and 0.67 (95% CI 0.46–0.99), respectively. The effect of diabetes on the risk of infection and death from COVID-19 was slightly higher in the HMPC population than in the HDC population (HRs for infection: 1.37 95% CI 1.22–1.53 vs. 1.20 95% CI 1.14–1.25; HRs for mortality: 3.96 95% CI 1.82–8.60 vs. 1.71 95% CI 1.50–1.95, respectively). No substantial difference in the strength of the association was observed between obesity or other comorbidities and SARS-CoV-2 infection. Similarly for COVID-19 mortality, HRs for obesity (HRs: 18.92 95% CI 4.48–79.87 vs. 3.91 95% CI 2.69–5.69) were larger in HMPC than in the HDC population, but differences could be due to chance. Among the population with diabetes, the HMPC group showed similar incidence (IRR: 0.99 95% CI: 0.88–1.12) and mortality (MRR: 0.89 95% CI: 0.49–1.61) to that of HDC individuals. The effect of obesity on incidence was similar in both HDC and HMPC populations (HRs: 1.73 95% CI 1.41–2.11 among HDC vs. 1.41 95% CI 0.63–3.17 among HMPC), although the estimates were very imprecise. Despite a higher prevalence of diabetes and a stronger effect of diabetes on COVID-19 mortality in HMPC than in the HDC population, our cohort did not show an overall excess risk of COVID-19 mortality in immigrants.

In 2024, almost ****** U.S. dollars were spent per diabetic patient in the United States, making it the country with the second-highest average cost per person. Switzerland had the highest per-person spending on diabetes, with over ** thousand U.S. dollars per patient. Lowest spending countries When viewing diabetes-related costs worldwide, it becomes apparent that there are significant disparities between countries. The ten countries with the lowest average annual diabetes-related health expenditures per person were all African and Asian countries. The Bangladesh stood at the top of the list in 2024, with an average spending of about ** U.S. dollars per person. Other countries on this list included Pakistan, the Democratic Republic of the Congo, and Madagascar. Anti-diabetic revenue Revenue generated by anti-diabetic products has increased as the number of diabetics worldwide has risen. Novo Nordisk is one of the leading companies in diabetes care, with around ** percent of the company's revenue generated through its diabetes care segment.

The average for 2021 based on 53 countries was 6.14 percent. The highest value was in Mauritius: 22.6 percent and the lowest value was in Benin: 1.1 percent. The indicator is available from 2000 to 2021. Below is a chart for all countries where data are available.

BackgroundHigh body mass index (BMI) plays a critical role in the initiation and development of type 2 diabetes (T2D). Up to now, far too little attention has been paid to the global burden of T2D attributable to high BMI. This study aims to report the deaths and disability-adjusted life years (DALYs) of T2D related to high BMI in 204 countries and territories from 1990 to 2019.MethodsData on T2D burden attributable to high BMI were retrieved from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019. The global cases, age-standardized rates of mortality (ASMR), and disability-adjusted life years (ASDR) attributable to high BMI were estimated by age, sex, geographical location, and socio-demographic index (SDI). The estimated annual percentage change (EAPC) was calculated to quantify the trends of ASMR and ASDR during the period 1990–2019.ResultsGlobally, there were 619,494.8 deaths and 34,422,224.8 DALYs of T2D attributed to high BMI in 2019, more than triple in 1990. Moreover, the pace of increase in ASMR and ASDR accelerated during 1990–2019, with EAPC of 1.36 (95% CI: 1.27 to 1.45) and 2.13 (95% CI: 2.10 to 2.17) separately, especially in men, South Asia, and low-middle SDI regions. Oceania was the high-risk area of standardized T2D deaths and DALYs attributable to high BMI in 2019, among which Fiji was the country with the heaviest burden. In terms of SDI, middle SDI regions had the biggest T2D-related ASMR and ASDR in 2019.ConclusionThe global deaths and DALYs of T2D attributable to high BMI substantially increased from 1990 to 2019. High BMI as a major public health problem needs to be tackled properly and timely in patients with T2D.

AimTo report the point prevalence, deaths and disability-adjusted-life-years (DALYs) due to type 2 diabetes and its attributable risk factors in 204 countries and territories during the period 1990-2019.MethodsWe used the data of the Global Burden of Disease (GBD) Study 2019 to report number and age-standardised rates per 100 000 population of type 2 diabetes. Estimates were reported with 95% uncertainty intervals (UIs).ResultsIn 2019, the global age-standardised point prevalence and death rates for type 2 diabetes were 5282.9 and 18.5 per 100 000, an increase of 49% and 10.8%, respectively, since 1990. Moreover, the global age-standardised DALY rate in 2019 was 801.5 per 100 000, an increase of 27.6% since 1990. In 2019, the global point prevalence of type 2 diabetes was slightly higher in males and increased with age up to the 75-79 age group, decreasing across the remaining age groups. American Samoa [19876.8] had the highest age-standardised point prevalence rates of type 2 diabetes in 2019. Generally, the burden of type 2 diabetes decreased with increasing SDI (Socio-demographic Index). Globally, high body mass index [51.9%], ambient particulate matter pollution [13.6%] and smoking [9.9%] had the three highest proportions of attributable DALYs.ConclusionLow and middle-income countries have the highest burden and greater investment in type 2 diabetes prevention is needed. In addition, accurate data on type 2 diabetes needs to be collected by the health systems of all countries to allow better monitoring and evaluation of population-level interventions.

Diabetes Diet Market Outlook

The global diabetes diet market size was valued at approximately USD 8.5 billion in 2023, projected to grow at a robust CAGR of 5.9% reaching around USD 14.9 billion by 2032. This growth trajectory is primarily fueled by the increasing prevalence of diabetes worldwide, which is urging a shift towards specialized dietary plans to manage the condition effectively. The burgeoning awareness regarding the benefits of a diabetes-specific diet, combined with an increase in health-consciousness among consumers, is driving significant demand in this market. Furthermore, the technological advancements in food processing and the introduction of innovative diabetes-friendly products are anticipated to bolster market expansion over the coming years.

The surge in diabetic populations globally is a major growth factor for the diabetes diet market. In many parts of the world, lifestyle changes and dietary shifts have led to a sharp rise in diabetes cases, particularly Type 2 diabetes. With urbanization, sedentary lifestyles, and the prevalence of unhealthy eating habits contributing to this rise, the need for dietary interventions has become more pronounced. Diabetes-specific diets play a crucial role in managing blood glucose levels, which in turn reduces the risk of complications associated with the disease. As healthcare professionals increasingly recommend tailored diet plans as part of diabetes management, the demand for specialized products continues to rise, fostering market growth.

The growing geriatric population also contributes significantly to the diabetes diet market’s expansion. Older individuals are more susceptible to Type 2 diabetes due to various factors, including reduced physical activity and metabolic changes. This demographic shift is leading to an increased market for diabetes-friendly dietary solutions tailored to meet the nutritional needs of older adults. Moreover, as life expectancy increases, the need for long-term diabetes management solutions, including appropriate diets, becomes more critical, further propelling market demand. The development of age-specific dietary products that cater to the geriatric population's unique requirements is becoming a focal point for manufacturers, thus driving innovation in the market.

Technological advancements and product innovation are also key drivers of market growth. The introduction of low-calorie sweeteners, meal replacements, and low-carbohydrate foods offers diabetic consumers a wider variety of choices that cater to their nutritional needs and preferences. These innovations are driven by a surge in research and development efforts aimed at enhancing the nutritional content and taste of diabetes-friendly products. Additionally, the growing trend of personalized nutrition, which involves tailoring diet plans based on individual health conditions, is encouraging manufacturers to invest in novel food solutions. This trend is expected to continue fueling the diabetes diet market as consumers seek products that align with their health goals and dietary restrictions.

The regional outlook for the diabetes diet market is promising, with North America leading due to its high diabetes prevalence and well-established healthcare infrastructure. In Europe, the market is driven by increasing health-consciousness and governmental initiatives promoting healthy lifestyles. The Asia Pacific region, exhibiting the highest growth rate, is fueled by rising diabetes incidences and growing awareness about diabetes management. Latin America and the Middle East & Africa are also witnessing market expansion due to improved healthcare access and increasing diabetes awareness campaigns. Each region's unique demographic and economic factors are shaping the growth trajectory of the diabetes diet market and creating opportunities for tailored market strategies.

Product Type Analysis

The diabetes diet market, segmented by product type, encompasses meal replacements, low-calorie sweeteners, low-carbohydrate foods, and other tailored food products. Meal replacements are gaining traction as they offer convenient solutions for individuals managing their diabetes. These products are designed to provide balanced nutrition while controlling carbohydrate intake, making them attractive to busy consumers. The market for meal replacements is being driven by the demand for easy-to-prepare options that do not compromise on nutritional value. Manufacturers are increasingly focusing on enhancing the taste and texture of these products to appeal to a wider audience, further driving their popularity.

Low-calorie

Type-1 Diabetes Treatment Market Outlook

The global Type-1 Diabetes Treatment market size is projected to grow significantly from USD 7.2 billion in 2023 to an estimated USD 12.6 billion by 2032, at a compound annual growth rate (CAGR) of 6.5%. The market growth is primarily driven by the rising prevalence of Type-1 diabetes worldwide, coupled with advancements in medical technology and treatment methods. Additionally, increasing awareness and early diagnosis of the disease have been pivotal in expanding the market's reach.

One of the major growth factors for the Type-1 Diabetes Treatment market is the continuous development and approval of innovative insulin delivery systems. Technologies such as insulin pumps, continuous glucose monitors, and artificial pancreas systems are revolutionizing diabetes care by offering more precise and convenient methods for managing blood sugar levels. These advancements not only improve the quality of life for patients but also reduce long-term complications associated with poor blood glucose control, thereby driving market expansion.

Another significant growth driver is the increasing investment in research and development by pharmaceutical companies. Efforts to discover new treatment modalities, including non-insulin therapies and regenerative medicine approaches like pancreas and islet cell transplantation, are creating new opportunities within the market. Additionally, collaborations between academic institutions and biotech firms are accelerating the pace of innovation, bringing novel therapies closer to commercial availability.

The market is also supported by favorable government initiatives and policies aimed at improving diabetes care. Many countries are implementing national diabetes programs that include guidelines for early diagnosis, comprehensive care plans, and subsidies for treatment costs. These programs are essential in increasing access to effective treatments, particularly in low and middle-income countries where the burden of diabetes is rising rapidly.

In recent years, Diabetes Stem Cell Therapy has emerged as a promising area of research in the treatment of Type-1 diabetes. This innovative approach involves the use of stem cells to regenerate insulin-producing beta cells in the pancreas, potentially offering a more permanent solution to insulin dependency. Researchers are exploring various sources of stem cells, including embryonic stem cells and induced pluripotent stem cells, to develop effective therapies. The ultimate goal is to restore the body's ability to produce insulin naturally, thereby reducing or eliminating the need for external insulin administration. While still in the experimental stages, early clinical trials have shown encouraging results, paving the way for future advancements in this field.

Regionally, North America dominates the Type-1 Diabetes Treatment market, accounting for the largest share due to high healthcare expenditure, advanced healthcare infrastructure, and significant investment in diabetes research. Europe follows closely, with a strong focus on improving healthcare outcomes and increasing awareness about diabetes management. The Asia Pacific region is expected to witness the highest growth rate during the forecast period, driven by the rising prevalence of diabetes, improving healthcare infrastructure, and increasing government initiatives to enhance diabetes care. Latin America and the Middle East & Africa also show promising growth potential, although these markets are currently smaller in size compared to North America and Europe.

Insulin Therapy Analysis

Insulin therapy remains the cornerstone of Type-1 diabetes treatment, accounting for a significant share of the market. The evolution of insulin formulations, including rapid-acting, long-acting, and intermediate-acting insulins, has provided patients with more options to tailor their treatment plans to their specific needs. Innovations such as biosimilar insulins have also made treatments more accessible by offering cost-effective alternatives to branded products. Continuous advancements in insulin delivery systems, such as smart insulin pens and pumps, are further enhancing the efficacy and convenience of insulin therapy.

Recent developments in insulin therapy include the advent of ultra-rapid-acting insulins, which aim to better mimic the body's natural insulin response to meals. These insulins provide faster onset and shorter durat